Piramal Pharma Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Piramal Pharma Ltd is ₹ 168.3 as of 07 May 10:23 . The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 0 on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 3 years The Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 years The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The revenue of Sun Pharma Advanced Research Company Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 8.45 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The ebitda of Sun Pharma Advanced Research Company Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -69 crore. This represent the decline of -100% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.

FAQs for the comparison of Piramal Pharma Ltd and Sun Pharma Advanced Research Company Ltd

Which company has a larger market capitalization, Piramal Pharma Ltd or Sun Pharma Advanced Research Company Ltd?

Market cap of Piramal Pharma Ltd is 21,945 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 5,096 Cr

What are the key factors driving the stock performance of Piramal Pharma Ltd and Sun Pharma Advanced Research Company Ltd?

The stock performance of Piramal Pharma Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Piramal Pharma Ltd and Sun Pharma Advanced Research Company Ltd?

As of May 7, 2026, the Piramal Pharma Ltd stock price is INR ₹165.1. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹157.05.

How do dividend payouts of Piramal Pharma Ltd and Sun Pharma Advanced Research Company Ltd compare?

To compare the dividend payouts of Piramal Pharma Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.